Silenced ZNF154 is associated with longer survival in resectable pancreatic cancer

Wiesmüller F, Kopke J, Aust D, Roy J, Dahl A, Pilarsky C, Grützmann R (2019)

Publication Type: Journal article

Publication year: 2019

Journal

International Journal of Molecular Sciences MDPI

Book Volume: 20

Article Number: 5437

Journal Issue: 21

DOI: 10.3390/ijms20215437

Abstract

Pancreatic cancer has become the third leading cause of cancer-related death in the Western world despite advances in therapy of other cancerous lesions. Late diagnosis due to a lack of symptoms during early disease allows metastatic spread of the tumor. Most patients are considered incurable because of metastasized disease. On a cellular level, pancreatic cancer proves to be rather resistant to chemotherapy. Hence, early detection and new therapeutic targets might improve outcomes. The detection of DNA promoter hypermethylation has been described as a method to identify putative genes of interest in cancer entities. These genes might serve as either biomarkers or might lead to a better understanding of the molecular mechanisms involved. We checked tumor specimens from 80 patients who had undergone pancreatic resection for promoter hypermethylation of the zinc finger protein ZNF154. Then, we further characterized the effects of ZNF154 on cell viability and gene expression by in vitro experiments. We found a significant association between ZNF154 hypermethylation and better survival in patients with resectable pancreatic cancer. Moreover, we suspect that the cell growth suppressor SLFN5 might be linked to a silenced ZNF154 in pancreatic cancer.

Authors with CRIS profile

Felix Wiesmüller Department of Surgery Christian Pilarsky Professur für Chirurgische Forschung Robert Grützmann Lehrstuhl für Allgemein- und Viszeralchirurgie

Involved external institutions

Technische Universität Dresden DE Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden DE Germany (DE) Staburo GmbH DE Germany (DE) Asklepios Klinik Weissenfels DE Germany (DE)

How to cite

APA:

Wiesmüller, F., Kopke, J., Aust, D., Roy, J., Dahl, A., Pilarsky, C., & Grützmann, R. (2019). Silenced ZNF154 is associated with longer survival in resectable pancreatic cancer. International Journal of Molecular Sciences, 20(21). https://doi.org/10.3390/ijms20215437

MLA:

Wiesmüller, Felix, et al. "Silenced ZNF154 is associated with longer survival in resectable pancreatic cancer." International Journal of Molecular Sciences 20.21 (2019).

BibTeX: Download